Ryan Green

Ryan Green is a private-markets investor-relations and capital-formation professional with roughly two decades of experience. He is currently COO & Head of Investor Relations at Eckuity Capital, a New York–based healthcare growth-equity platform, where he leads global fundraising, investor relations, and strategic-partnership initiatives, and works alongside the investment team on syndication and co-investment opportunities across the growth portfolio.

Before Eckuity, Green held senior capital-development and business-development roles at a series of established global private-markets firms. He was a Director, Business Development at Abbott Capital Management (a New York private-equity fund-of-funds and co-investment manager) from roughly September 2017 to March 2022, and subsequently served as Principal / Head of US Business Development at Unigestion's private-equity business. Earlier in his career he worked at LGT Capital Partners and Commonfund, expanding institutional investor relationships across North America, Europe, and the Middle East, and he was a Partner at Seasons Capital Management, where he led fundraising and investor engagement for venture- and growth-stage healthcare and technology funds.

Public database and bio sources indicate he holds a degree from Rutgers University and has additional executive education associated with the Yale School of Management. He is based in the New York City area.

• Green's professional role is raising and stewarding institutional capital (LPs, family offices, strategic partners) rather than leading deals — evaluate him as a fundraising/IR leader, not a check-writing angel.
• His current firm, Eckuity Capital, invests in commercial-stage life-sciences companies with regulatory approval and commercial traction — "positioned between seed-stage VCs and mega-buyout PE firms."
• Sector verticals at Eckuity: MedTech / diagnostics, tech-enabled healthcare (HealthTech/Digital Health), and Biotech/Therapeutics services.
• Typical entry point is Series C and beyond (growth equity), with a stated emphasis on "commercial viability" and a "clear exit pathway" (IPO, strategic sale, or licensing).
• Across his career he has focused on venture- and growth-stage healthcare and technology strategies (notably at Seasons Capital and now Eckuity).